The Risk Evaluation and Mitigation Strategy (REMS) Public Dashboard: Improving Transparency of Regulatory Activities

被引:0
|
作者
Gita A. Toyserkani
Joann H. Lee
Esther H. Zhou
机构
[1] US Food and Drug Administration (FDA),Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research
来源
Pharmaceutical Medicine | 2023年 / 37卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
This brief paper aims to describe the Risk Evaluation and Mitigation Strategy (REMS) Public Dashboard launched by the US Food and Drug Administration (FDA) in December 2021. The FDA REMS Public Dashboard can be accessed through the REMS@FDA website. The dashboard was developed in Qlik Sense® to support a user-friendly interactive web-based tool that allows healthcare providers, patients, researchers, pharmaceutical companies, and regulators to readily access and visualize REMS information. The dashboard includes eight separate pages to capture information on all REMS, active REMS, REMS with elements to assure safe use, shared system REMS, REMS modifications, REMS revisions, released REMS, and REMS Summary; for REMS programs approved from 2008 to the present. Most of the pages allow users to choose different REMS characteristics to visualize and stratify the data by variables such as REMS approval time, application type, or REMS elements. This interactive platform is intended to allow users to quickly visualize trends over time and locate details of the REMS programs to inform emerging research and regulatory issues in the context of current drug safety. The FDA continues to explore ways to enhance public access of the REMS information in near real-time through the REMS Public Dashboard.
引用
收藏
页码:349 / 353
页数:4
相关论文
共 50 条
  • [1] The Risk Evaluation and Mitigation Strategy (REMS) Public Dashboard: Improving Transparency of Regulatory Activities
    Toyserkani, Gita A.
    Lee, Joann H.
    Zhou, Esther H.
    PHARMACEUTICAL MEDICINE, 2023, 37 (5) : 349 - 353
  • [2] Correction to: The Risk Evaluation and Mitigation Strategy (REMS) Public Dashboard: Improving Transparency of Regulatory Activities
    Gita A. Toyserkani
    Joann H. Lee
    Esther H. Zhou
    Pharmaceutical Medicine, 2023, 37 : 355 - 355
  • [3] The Risk Evaluation and Mitigation Strategy (REMS) Public Dashboard: Improving Transparency of Regulatory Activities (vol 37, pg 349, 2023)
    Toyserkani, Gita A.
    Lee, Joann H.
    Zhou, Esther H.
    PHARMACEUTICAL MEDICINE, 2023, 37 (5) : 355 - 355
  • [5] Risk Evaluation and Mitigation Strategy (REMS) - Process, Procedure and Management
    Khurana, T.
    ALLERGOLOGIE, 2024, 47 (06)
  • [6] Contraception Special Issue on the mifepristone Risk Evaluation and Mitigation Strategy (REMS)
    Cleland, Kelly
    Foster, Angel M.
    Gomez, Anu Manchikanti
    Raymond, Elizabeth G.
    Westhoff, Carolyn L.
    CONTRACEPTION, 2021, 104 (01) : 1 - 3
  • [7] Curbing the Opioid Epidemic in the United States The Risk Evaluation and Mitigation Strategy (REMS)
    Nelson, Lewis S.
    Perrone, Jeanmarie
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 308 (05): : 457 - 458
  • [8] Implications of Risk Evaluation and Mitigation Strategy (REMS) Programs for Managed Care Pharmacy
    Gandhi, Gaurang
    Chon, Ashley
    Johnson, Nik
    Kidder, Phyllis A.
    Lee, Peter
    Leung, Kevin
    Ma, Ingrid
    Ness, Stacey
    Sampsel, Elizabeth
    Schlaifer, Marissa
    Seifert, Randall
    Sternaman, Debora B.
    Raval, Kalindi
    JOURNAL OF MANAGED CARE PHARMACY, 2012, 18 (03): : 268 - 275
  • [9] A Smartphone Application for the Completion of IMiD Risk Evaluation and Mitigation Strategy (REMS) Patient Surveys: The REMS Companion App
    Sweeney, N.
    Chapman, J.
    Varandas, J.
    McWilliams, R.
    Roldan, J.
    Chan-Liston, M. L.
    DRUG SAFETY, 2021, 44 (12) : 1465 - 1466
  • [10] Risk Evaluation and Mitigation Strategy (REMS): FDA Perspective on What Physicians Need to Know
    Slatko, Gary H.
    AMERICAN FAMILY PHYSICIAN, 2015, 92 (09) : 771 - 772